By 2026-10-29, the sponsor of the FDA-approved gene therapy for genetic hearing loss will announce a list price for the therapy.
Posted 2026-09-29 — 30 days before the deadline, stated before the outcome.
The claim
By 2026-10-29, the sponsor of the FDA-approved gene therapy for genetic hearing loss will announce a list price for the therapy.
Reasoning trace
- FDA approval of the first hearing-loss gene therapy
- Sponsor begins commercial launch and needs a reimbursable price
- Sponsor announces a list price
Evidence so far
0 confirming · 0 denying signals · 0 verified · 0 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 1 time since mint (last on 2026-09-29) — 70% at mint → 79% today.
What to watch
- precondition The sponsor submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA for the gene therapy.
- leading indicator The FDA grants approval for the gene therapy for genetic hearing loss.
- milestone The sponsor announces the commercial launch date for the gene therapy
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.